報價延遲最少15分鐘:2026/01/07 15:55 EST
盤後時段
|
||||
|
-- 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
12.14
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.09/-1.85
|
|
企業價值
406.50M
|
| 資產負債 |
|
每股賬面淨值
2.76
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
829.13K
|
|
每股收益
0.00
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder. |
